Adaptimmune

ABINGDON, OXFORDSHIRE, X0 · CIK 0001621227 · Biotech · Public

Engineered T-cell cancer immunotherapy products

adaptimmune.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$104M
1 Form D · Oct 2014
144 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$103,809,789
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2823Ovid Therapeutics—$106M
2824LEAP THERAPEUTICS, INC.—$105M
2825CENTRILLION BIOSCIENCES, INC.——
2826Adaptimmune—$104M
2827Civitas Therapeutics—$104M
2828AVATAR MEDICAL, LLC——
2829NEPHROGEN INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Ali BehbahaniDirector
  • Dr. Jonathan KnowlesDirector
  • Ian LaingDirector
  • David MottDirector
  • James NobleDirector · Executive Officer
  • Elliott SigalDirector
  • Peter ThompsonDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.